Drugs / NNC0363-1063
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07305805 | Dec 2025 → Apr 2026 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06685185 | Nov 2024 → Mar 2026 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0363-1063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07305805 ↗ |
| Modality | Protein / enzyme biologic | “novel insulin NNC0363-1063” NCT07305805 ↗ |
| Route | Subcutaneous | “NNC0363-1063 will be administered subcutaneously.” NCT06685185 ↗ |